Bansi Desai

“So, my first question is on the domestic growth. So, you alluded, you know, we should come back to industry growth, you know, shortly. So, question is, what is going to drive that and in what timeframe should we expect MQR to beat the industry growth?”

“So, there is no element of low base here, right? You know, for the last 4-6 quarters, we've seen good growth, but we expect this kind of momentum to continue.”

“So, firstly, on Sayadri, you know, historically, when, you know, Manipal has acquired assets, we've seen that, you know, we've invested into those assets in the initial years, and, you know, we are likely to Do the same with Sayadri as we integrate the asset and as we invest into specialties and everything.”

“In your opening remarks, you mentioned, you know, your confidence in Kohans' recovery stems from the fact that, you know, there is scientific capabilities. And we appreciate the fact that, you know, when it comes to ABCs and oligonucleotides, Kohans does have a differentiated positioning.”

“So, my first question is on semaglutide API. If you could share, have we started our commercial supply on this product to domestic players?”